Skip to main content
WeightCited

CLA per Obesity

B

Cochrane meta-analysis of 18 RCTs (n=807) found CLA at 3.2 g/day reduced body fat mass by 1.33 kg over 6-12 months without significant change in body weight, suggesting lean mass preservation. A 2-year RCT (n=134) found sustained fat reduction. Effects are modest and require long-term use.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'weightcited.com'; const params = 'ingredient\u003Dcla\u0026condition\u003Dobesity'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

In sintesi

Cochrane meta-analysis of 18 RCTs (n=807) found CLA at 3.2 g/day reduced body fat mass by 1.33 kg over 6-12 months without significant change in body weight, suggesting lean mass preservation. A 2-year RCT (n=134) found sustained fat reduction. Effects are modest and require long-term use.

Key Statistics

18

Studi

807

Partecipanti

Positive

B

Grado

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosaggi di uso comune

general:
3.2-6.4 g/day mixed isomers
bodycomposition:
3.4 g/day (50:50 c9,t11:t10,c12 blend)
minimumeffective:
3.2 g/day for ≥12 weeks

Limite massimo: 6 g/day; higher doses may worsen insulin sensitivity

Momento migliore per l'assunzione: With meals; divide dose across 2-3 meals

Safety & Side Effects

Effetti collaterali segnalati

  • GI discomfort
  • May worsen insulin sensitivity at high doses
  • Possible HDL reduction
  • Fatty liver (in some rodent studies)

Interazioni note

  • Diabetes medications (may affect insulin sensitivity)
  • Blood thinners (theoretical)

Livello di assunzione massimo tollerabile: 6 g/day; higher doses may worsen insulin sensitivity

Consultare sempre il proprio medico prima di iniziare qualsiasi integratore.Consultate sempre il vostro medico prima di iniziare qualsiasi integratore.

Frequently Asked Questions

Does CLA help with Obesity?
Based on 18 studies with 807 participants, there is moderate evidence from clinical studies that CLA may support Obesity management. Our evidence grade is B (Good Evidence).
How much CLA should I take for Obesity?
Studies have used various dosages. A commonly studied range is 3.2-6.4 g/day mixed isomers. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of CLA?
Reported side effects may include GI discomfort, May worsen insulin sensitivity at high doses, Possible HDL reduction, Fatty liver (in some rodent studies). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for CLA and Obesity?
We rate the evidence as Grade B (Good Evidence). This rating is based on 18 peer-reviewed studies with 807 total participants. The overall direction of effect is positive.

Related Evidence

Avvertenza FDA: Queste affermazioni non sono state valutate dalla Food and Drug Administration. I prodotti e le informazioni presenti su questo sito web non sono destinati a diagnosticare, trattare, curare o prevenire alcuna malattia. I gradi di evidenza presentati si basano sulla nostra analisi della ricerca pubblicata e sottoposta a revisione paritaria e non costituiscono consulenza medica. Consultate sempre il vostro medico prima di iniziare qualsiasi regime di integrazione.